Physician profile
Anne B Bryan
NPI 1255314415
$5,485.33
in general payments reported to CMS, 2019-2025
24 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $73.47 · 2021: $722 · 2022: $1,153 · 2023: $1,214 · 2024: $775 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.54 |
| Education | $123.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,286.03 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Genzyme Corporation | $944.89 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $888.40 | 2019-2025 | |
| Janssen Biotech, INC. | $295.15 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $286.26 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $235.25 | 2019-2025 | Taltz, Ebglyss |
| Leo Pharma INC. | $220.00 | 2019-2023 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $157.16 | 2022-2024 | Sotyktu |
| Organon LLC | $150.32 | 2025 | Vtama |
| Celgene Corporation | $135.62 | 2019 | |
| Sun Pharmaceutical Industries INC. | $132.26 | 2022 | |
| Incyte Corporation | $126.73 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $116.38 | 2024-2025 | Nemluvio |
| Pfizer INC. | $115.35 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $110.66 | 2019-2025 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $67.09 | 2019-2022 | |
| Dermavant Sciences, INC. | $61.26 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.52 | 2023 | Spevigo, Cyltezo |
| Almirall LLC | $27.32 | 2021-2022 | |
| Ucb, INC. | $23.11 | 2024 | Bimzelx |
| Nabriva Therapeutics, Plc | $22.42 | 2022 | |
| Mallinckrodt Hospital Products INC. | $18.26 | 2025 | Acthar |
| Genentech USA, INC. | $15.84 | 2023 | Xolair |
| Arcutis Biotherapeutics, INC. | $14.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.